Incyte

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development and commercialization of proprietary therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products such as JAKAFI (ruxolitinib), and ICLUSIG (ponatinib). The company was founded by Roy A. Whitfield in April 1991 and is headquartered in Wilmington, DE.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Incyte reports robust revenue growth and strategic focus on pediatric market

Incyte's Q4 2022 earnings call showcased strong revenue growth, driven by successful product launches and advancements in the clinical development pipeline.
While facing challenges in market adoption and operational dynamics, Incyte's strategic focus on pediatric patients and engagement with healthcare professionals positions it well for future growth.
Opportunities lie in expanding market reach for Opzelura, exploring new therapeutic applications, and enhancing market penetration efforts through strategic partnerships and product differentiation.
Overall, Incyte's performance reflects a balance of solid financial results, strategic investments in innovation, and a focus on addressing market challenges to drive sustainable growth.

Incyte (INCY) reports robust Q1 growth, eyes international expansion

Incyte's strong Q1 performance driven by Jakafi and Opzelura demand sets the stage for future growth and diversification.
Focusing on high-potential programs and commitment to biologics position Incyte for value creation and market expansion.
Challenges in inventory management and pricing strategies are being addressed as the company eyes multiple launches and international expansion.

Incyte excels in Q2 with strong revenue growth and strategic advancements

Incyte's Q2 2023 performance showcased strong revenue growth driven by key products and successful clinical studies, positioning the company for future success.
The company's focus on innovative therapies and strategic leadership appointments underpin its commitment to advancing in oncology and dermatology.
While facing challenges in revenue guidance and clinical trial progress, Incyte's openness to M&A and growth opportunities signals a proactive approach to driving future expansion.

Incyte reports strong Q3 earnings, focuses on pipeline expansion

Incyte's Q3 earnings reflect robust revenue growth and positive clinical development progress. The company is navigating challenges of patent expiration while focusing on expanding market access and advancing pipeline programs.

Incyte reports robust 2023 earnings, eyes global growth opportunities

Incyte's strong financial performance in 2023 was driven by revenue growth across key products and successful launches like Opzelura.
The company's focus on innovative clinical programs and R&D advancements positions it well for future growth and market expansion.
Challenges in reimbursement, patient retention, and regulatory compliance require strategic planning, while opportunities in global partnerships and market expansion offer avenues for continued success.

Incyte reports strong Q1 growth, eyes oncology opportunities ahead

Incyte delivered solid financial performance in Q1 2024, driven by revenue growth and strong product sales.
The company faces challenges from operational disruptions and competitive landscapes but is well-positioned for growth.
Strategic strengths in pipeline development, financial stability, and market focus position Incyte for future success.
Opportunities in new product launches, market expansion, and capital deployment offer avenues for continued growth.

Incyte reports robust Q2 earnings, raises guidance on key products

Incyte's Q2 2024 performance reflects strong revenue growth, strategic acquisitions, and a focus on high-potential pipeline assets. While facing challenges with rising expenses and pipeline restructuring, the company is well-positioned to capitalize on opportunities in innovative drug development and positive patient outcomes.

Incyte reports robust Q3 earnings, eyes high-impact launches by 2030

Overall, Incyte's Q3 2024 earnings call showcased strong revenue growth, promising product developments, and a focus on expanding its product portfolio and pipeline for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. The company was founded in April 1991 and is headquartered in Wilmington, DE.

Is  (INCY) Outperforming Other Medical Stocks This Year?

Has Incyte (INCY) Outpaced Other Medical Stocks This Year?

ACADIA Pharma

Alexion Pharma

Anika Therapeutics

Gilead Sciences

Regeneron Pharmaceuticals

Vertex Pharmaceuticals

Biotech Stock Outlook: M&A Activity Retains Growth Streak

Does Incyte (INCY) have what it takes to be a top stock pick for momentum investors? Let's find out.

Here's Why Momentum Investors Will Love Incyte (INCY)

Incyte is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

Moving Average Crossover Alert: Incyte

J.P. Morgan Alerian MLP Index ETN

ANSYS

Humana

International Flavors & Fragrances

JPMorgan Chase & Co

Pentair

Varian Medical Systems

While value investors look for stocks that have become priced too low or high based on fundamental metrics such as earnings, revenue and debt, technical traders base their buys and sells off of recent trading action in a stock’s charts.

9 Most Overbought Stocks In The S&P 500

Incyte's NDA For Pemigatinib Drug Accepted, But It Is Not A One Hit Wonder

Strong sales for the company's main drug and potential new applications and treatments have pushed the pharma stock up 48% in 2019.

Why Incyte Stock Climbed 12.2% in November

Bruker

Edwards Lifesciences

Inmode Ltd

The best health care stocks to watch have several commonalities including a streak of earnings growth. It's important to keep tabs on high-ranking health care stocks with strong metrics.

Why You Should Keep An Eye On These 5 Leading Health Care Stocks

The best biotech companies to invest in tend to have a commonality: a strong streak of earnings growth.
The post Looking For Growth?

Looking For Growth? Take A Look At These Biotechnology Stocks

Incyte (INCY) reported earnings 30 days ago. What's next for the stock?

Why Is Incyte (INCY) Up 12.5% Since Last Earnings Report?

The FDA accepts and grants priority review to Incyte's (INCY) new drug application for pemigatinib as a second-line treatment for patients with FGFR2 translocated cholangiocarcinoma.

Incyte's NDA for Pemigatinib Gets FDA's Priority Review Tag

Incyte (INCY) Is Up 1.88% in One Week: What You Should Know

We highlight a few principal players from the biotech sector, which are likely to witness a winning run in the near term.

4 Big Biotech Stocks Worth Considering Post Q3 Earnings

Incyte: A Buy On Revenue, EPS Growth And Strong Pipeline

Biogen

Celgene

DaVita

HCA Healthcare

Pfizer

Teleflex

Health Care Select Sector SPDR Fund

DENTSPLY SIRONA

These are the health care stocks with the best value, fastest growth, and most momentum for November.

Top Health Care Stocks for November 2019

Coherus BioSciences

The biotechnology industry has lagged the broader market so far this year, but these four stocks have done pretty well and should continue to do so.

4 Biotech Stocks That Could Keep Beating Wall Street

The company reported third-quarter 2019 operating results and raised full-year 2019 guidance for its lead drug product.

Here's Why Incyte Corporation Jumped 13.0% in October

Incyte (INCY) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Will Incyte (INCY) Gain on Rising Earnings Estimates?

Incyte: An Undervalued Biotech With Catalysts

Slack

It's impressive what a solid quarter or a positive analyst note will do for a publicly traded company.

2 Stocks That Crushed It on Tuesday

Incyte Corporation's (INCY) CEO Hervé Hoppenot on Q3 2019 Results - Earnings Call Transcript

Incyte (INCY) reports better-than-expected results for the third quarter of 2019, owing to strong Jakafi sales.

Incyte (INCY) Beats on Q3 Earnings & Sales, Ups Jakafi View

Incyte (INCY) delivered earnings and revenue surprises of 26.15% and 2.34%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Incyte (INCY) Q3 Earnings and Revenues Top Estimates

Incyte earnings and revenue topped third-quarter views. Early Tuesday, Incyte stock rallied, signaling a move above a long-term technical level.

Incyte Earnings Top, Stock Pops

Amgen

Merck

Four drug/biotech stocks are scheduled to release third-quarter results on Oct 29. Let's see how these companies are placed before their earnings call.

News for Incyte Stock (INCY)